openPR Logo
Press release

Lawsuit filed for Investors in Teva Pharmaceutical Industries Limited (NYSE: TEVA)

07-22-2019 08:37 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares.

A lawsuit was filed on behalf of investors in Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares.

An investor, who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA), filed a lawsuit over alleged Securities Laws violations by Teva Pharmaceutical Industries Limited.

Investors who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Israel based Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide.
The first such investigation was initiated by the Attorney General (“AG”) of Connecticut in July 2014. Shortly thereafter, the United States Congress and United States Department of Justice each launched similar probes into skyrocketing prices of generic drugs. Since that time, Teva has been subject of intense public scrutiny concerning its alleged involvement in an industry-wide price-fixing scheme and other collusive misconduct in the U.S. generic drug market.

Since at least 2014, there has been intense public scrutiny into the rising prices of generic drugs, including Congressional hearings, calls for drug pricing legislation, and prosecutorial investigations.
On December 9, 2018, it was publicly disclosed that the scope of the State AGs’ investigation had expanded greatly to include 300 drugs and at least 16 companies, exposing “the largest cartel in the history of the United States.”

On May 10, 2019, a coalition of 44 states filed a 524-page antitrust complaint revealing previously undisclosed facts regarding Teva Pharmaceutical Industries Limited’s participation in the generic drug price-fixing conspiracy. Among other things, the action detailed Teva Pharmaceutical Industries Limited’s role as a “consistent participant” in the conspiracy, implementing price increases on upwards of 110 generic drugs and colluding with competitors regarding over 85 different generic drugs.

The plaintiff claims that between August 4, 2017 and May 10, 2019, the defendants made false and/or misleading statements denying that Teva “engaged in any conduct that would give rise to liability” in various antitrust proceedings and investigations that enveloped the company. In truth, and as Defendants failed to disclose to investors, (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.

Those who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in Teva Pharmaceutical Industries Limited (NYSE: TEVA) here

News-ID: 1808734 • Views: 757

More Releases from Shareholders Foundation

Investigation announced for Investors in Genworth Financial, Inc. (NYSE: GNW)
An investigation was announced concerning potential securities laws violations by Genworth Financial, Inc. in connection with certain financial statements. Investors who purchased shares of Genworth Financial, Inc. (NYSE: GNW), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Genworth Financial, Inc. (NYSE: GNW) concerning whether a
Investigation announced for Long-Term Investors in shares of Dropbox, Inc. (NASD …
An investigation was announced for investors in shares of Dropbox, Inc. (NASDAQ: DBX) concerning potential breaches of fiduciary duties by certain directors of Dropbox, Inc.. Investors who are current long term investors in Dropbox, Inc. (NASDAQ: DBX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: DBX stocks follows
Deadline in Lawsuit for Investors in shares of Trulieve Cannabis Corp. (OTC: TCN …
The Shareholders Foundation announced that a deadline is coming up on February 28, 2020 in the lawsuit filed for certain investors of Trulieve Cannabis Corp. (OTC: TCNN) over alleged securities laws violations by Trulieve Cannabis Corp. Investors who purchased shares of Trulieve Cannabis Corp. (OTC: TCNN) have certain options and there are strict and short deadlines running. Deadline: February 28, 2020. OTC: TCNN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Investigation announced for Investors in shares of Canaan Inc. (NASDAQ: CAN)
An investigation was announced concerning potential securities laws violations by Canaan Inc. in connection with certain financial statements. Investors who purchased shares of Canaan Inc. (NASDAQ: CAN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Canaan Inc. (NASDAQ: CAN regarding its business, its prospects and its operations were materially

All 5 Releases


More Releases for Teva

Global Generic Drugs Market 2018 - Valeant, Zydus Cadila, Hikma, Teva
Accord Market, recently published a detailed market research study focused on the “Generic Drugs Market” across the global, regional and country level. The report provides 360° analysis of “Generic Drugs Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Generic Drugs on the
Global Trazodone Hydrochloride (API) Market 2018 - Teva, Angelini, Mylan, Fermio …
Apex Market Reports, recently published a detailed market research study focused on the “Trazodone Hydrochloride (API) Market” across the global, regional and country level. The report provides 360° analysis of “Trazodone Hydrochloride (API) Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Trazodone
Global Capecitabine Market 2018 - Roche, Teva, Mylan, Hikma, Cipla
Apex Market Reports, recently published a detailed market research study focused on the “Capecitabine Market” across the global, regional and country level. The report provides 360° analysis of “Capecitabine Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Capecitabine on the basis of
Global Perphenazines Market 2018 - Teva, Sandoz, Endo, Mylan
Apex Market Reports, recently published a detailed market research study focused on the “Perphenazines Market” across the global, regional and country level. The report provides 360° analysis of “Perphenazines Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Perphenazines on the basis of
Global Calcitriol Market 2017- Teva, Strides Arcolab, Cadila Pharmaceuticals
Global Calcitriol Market 2017, presents a professional and in-depth study on the current state of the Calcitriol market globally, providing basic overview of Calcitriol market including definitions, classifications, applications and industry chain structure. Historical data available in the report elaborates on the development of the Calcitriol market on a global and regional level. The report compares this data with the current Calcitriol state of the market and thus discuss upon
Desipramine Market Size 2017-2022 Pfizer, Teva, Emcure, Novartis, Mylan
Global Desipramine Market Research Report Recently published a detailed market study on the "Desipramine Market" across the global, regional and country level. The report on the global Desipramine market uses the top-down and bottom-up approaches to define, analyze, and describe the market trends for the next five years. The Desipramine market report further provides production, capacity, Desipramine market price per region, gross margin, production cost, for all major regions and countries